Starling Oncology, Inc. (STLN) Free cash flow 2020–2025
Starling Oncology, Inc. (STLN) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$27.8MFY2025 · since FY2020: -$686,000 → -$27.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$27.8M | +8.4% |
| FY2024 | -$30.3M | +25.8% |
| FY2023 | -$40.9M | +39.2% |
| FY2022 | -$67.3M | -89.4% |
| FY2021 | -$35.5M | -5078.9% |
| FY2020 | -$686,000 | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More STLN financial trends
STLN RevenueSTLN Net incomeSTLN Net marginSTLN Gross profitSTLN Gross marginSTLN Operating incomeSTLN Operating marginSTLN Operating cash flowSTLN Capital expendituresSTLN Return on equitySTLN Stock buybacksSTLN Dividends paidSTLN Total assetsSTLN Total liabilitiesSTLN Shareholders’ equitySTLN overview →